Neurocrine Biosciences (NBIX) has an average rating of Outperform and price targets ranging from $76 to $154, according to analysts polled by Capital IQ....
Neurocrine Biosciences (NBIX) shares were down 4% in Tuesday afternoon trading after RBC downgraded the biopharmaceutical company's stock to sector perform...
Neurocrine Biosciences (NBIX) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $76 to...
Xenon Pharmaceuticals (XENE) said Wednesday said it was set to receive a payment of $15 million from its epilepsy joint venture partner Neurocrine...
| Address | 12780 El Camino Real San Diego, California 92130 |
| Phone | +1.858.617.7600 |
| Number of Employees | 585 |
| Recent SEC Filing | 01/18/2022 CT ORDER |
| Chief Executive Officer & Director | Kevin Charles Gorman |
| Vice President-Information Technology & Operations | Bill Wilson |
| Chief Financial Officer | Matthew C. Abernethy |
| Chief Research Officer | Dimitri E. Grigoriadis |
| Price Open | $72.94 |
| Previous Close | $72.80 |
| 52 Week Range | $71.88 - 120.27 |
| Market Capitalization | $7.1 B |
| Shares Outstanding | 94.9 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 02/03/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | 16.43 |
| Earnings per Share | $4.83 |
| Beta vs. S&P 500 | N/A |
| Revenue | $451.2 M |
| Net Profit Margin | 41.59% |
| Return on Equity | 35.89% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
